EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine

Artem Chayka, Michal Česnek, Erika Kužmová, Jaroslav Kozák, Eva Tloušt'ová, Alexandra Dvořáková, Timotej Strmeň, Břetislav Brož iD, Zuzana Osifová, Martin Dračínský, Helena Mertlíková-Kaiserová, Zlatko Janeba iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00323 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Artem Chayka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 160 00, Czech Republic. Hauptthemen laut MEDLINE: Receptors, Adrenergic, alpha-2, Yohimbine, Drug Design, Adrenergic alpha-2 Receptor Antagonists. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ?stav organick? chemie a biochemie Akademie ved Cesk? republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yohimbine, a natural indole alkaloid and a nonselective adrenoceptor antagonist, possesses potential benefits in treating inflammatory disorders and sepsis. Nevertheless, its broader clinical use faces challenges due to its low receptor selectivity. A structure-activity relationship study of novel yohimbine analogues identified amino esters of yohimbic acid as potent and selective ADRA2A antagonists. Specifically, amino ester 4n, in comparison to yohimbine, showed a 6-fold higher ADRA1A/ADRA2A selectivity index (SI > 556 for 4n) and a 25-fold higher ADRA2B/ADRA2A selectivity index. Compound 4n also demonstrated high plasma and microsomal stability, moderate-to-low membrane permeability determining its limited ability to cross the blood-brain barrier, and negligible toxicity on nontumor normal human dermal fibroblasts. Compound 4n represents an important complementary pharmacological tool to study the involvement of adrenoceptor subtypes in pathophysiologic conditions such as inflammation and sepsis and a novel candidate for further preclinical development to treat ADRA2A-mediated pathologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Adrenergic, alpha-2YohimbineDrug DesignAdrenergic alpha-2 Receptor AntagonistsHumansStructure-Activity RelationshipAnimals

Substanzen

Receptors, Adrenergic, alpha-2YohimbineAdrenergic alpha-2 Receptor AntagonistsADRA2A protein, human

Autor:innen und Institutionen

  • Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 160 00, Czech Republic.

ORCID-Profile: Břetislav Brož, Zlatko Janeba

Förderung

  • ?stav organick? chemie a biochemie Akademie ved Cesk? republiky

Zitieren

APA

Chayka, A., Česnek, M., Kužmová, E., Kozák, J., Tloušt'ová, E., Dvořáková, A., Strmeň, T., Brož, B., Osifová, Z., Dračínský, M., Mertlíková-Kaiserová, H., & Janeba, Z. (2024). Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00323

Vancouver

Chayka A, Česnek M, Kužmová E, Kozák J, Tloušt'ová E, Dvořáková A, et al. Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00323

BibTeX
@article{Chayka2024,
  author = {Chayka, Artem and Česnek, Michal and Kužmová, Erika and Kozák, Jaroslav and Tloušt'ová, Eva and Dvořáková, Alexandra and Strmeň, Timotej and Brož, Břetislav and Osifová, Zuzana and Dračínský, Martin and Mertlíková-Kaiserová, Helena and Janeba, Zlatko},
  title = {Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00323}
}
Kostenlos starten →